MethylGene Inc. is a publicly-traded biopharmaceutical company that is developing novel targeted drugs for the treatment of cancer and infectious disease. The Company is focused on its two lead molecules, MGCD265 for cancer and MGCD290 for fungal infections; both are currently in human clinical trials.
While MethylGene has discovered an impressive pipeline of molecules through its expertise in molecular biology and chemistry, it has chosen to focus on MGCD265 and MGCD290. We believe that these are both highly promising and differentiated product candidates. MethylGene has additional products in its pipeline which also have the potential to address current medical needs.
MethylGene was incorporated in 1995 and became publicly-traded in June 2004 on the Toronto Stock Exchange (TSX:MYG).